Telix Acquires ITM Isotope for $1.65B to Challenge Novartis in Radiopharma

Key points

• Telix will pay $1.65 billion upfront to acquire all shares of privately held ITM Isotope Technologies.
• Additional payments of up to $700 million are tied to regulatory approvals and sales milestones for ITM’s lead drug, ITM-11.
• The FDA rejected ITM-11 in August 2026 citing chemistry, manufacturing, and controls issues at a third-party facility.
• ITM is a key supplier of lutetium-177, an isotope used in Novartis’s Pluvicto and Lutathera, as well as Telix’s pipeline.
• The combined company is projected to generate $1.3 billion in revenue this year, up from ITM’s $273 million in 2025.

Background

The radiopharmaceutical sector has seen rapid growth since Novartis launched its first two treatments in 2018 and 2022. While the field was previously dominated by Novartis, new entrants like Telix and ITM are emerging to compete in the therapeutic market. Telix currently markets imaging agents for prostate and brain cancer and is developing radioligand therapies, including TLX591, which targets prostate cancer. This acquisition represents a strategic move to expand into neuroendocrine tumors and secure supply chain control for critical isotopes.

How outlets are covering it

STAT reported the merger as a significant consolidation in the radiopharmaceutical field, highlighting the creation of a well-resourced competitor to Novartis. Fierce Biotech emphasized the financial structure of the deal, noting that analysts are 'extremely bullish' on the combined entity’s growth prospects, particularly due to ITM’s vertical integration capabilities and the potential for ITM-11 to become a differentiated product. Yahoo Finance Australia focused on the market impact, noting that Telix shares fell 10% after the announcement, while also detailing the specific milestone payments tied to ITM-11’s regulatory success. All sources agree on the upfront cost of $1.65 billion, but Fierce Biotech provided the most detailed breakdown of the additional $700 million in potential payments, linking them to specific FDA approval timelines and sales thresholds.

Why it matters

This merger signals a shift in the radiopharmaceutical market from Novartis’s monopoly toward a more competitive landscape. By acquiring ITM, Telix secures a critical supply chain for lutetium-177 and gains access to a pipeline that could challenge Novartis’s blockbuster drugs. The deal also highlights the importance of manufacturing quality in FDA approvals, as the rejection of ITM-11 underscores the regulatory hurdles facing new entrants in this field. For investors, the merger represents a bet on the long-term growth of radioligand therapies and the ability of smaller companies to compete with established giants through strategic acquisitions.

What to watch

Telix and ITM must resolve the FDA’s concerns regarding the third-party manufacturing facility before the deal can close. ITM plans to refile for ITM-11, with the timing dependent on remediation efforts and discussions with the FDA. If approved, the combined company will focus on commercializing ITM-11 for gastroenteropancreatic neuroendocrine tumors and lung NETs, while also advancing Telix’s TLX591 for prostate cancer. The success of these efforts will determine whether the additional $700 million in milestone payments is triggered.